Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
Chronic myelogenous leukemia (CML) is a clonal disorder characterized by proliferation of cells that possess the bcr-abl fusion gene resulting in the production of one of two possible chimeric 210-kDa tyrosine kinase proteins. Since these chimeric proteins are expressed only in leukemic cells they have the potential to serve as tumor-specific antigens for cytotoxic T lymphocytes (CTL). Using the 12B1 murine leukemia cell line, derived by retroviral transformation of BALB/c bone marrow cells with the bcr-abl (b3a2) fusion gene, we have demonstrated that intravenous inoculation of 12B1 cells into BALB/c mice results in a disseminated acute leukemia analogous to human CML in blast crisis. Histological sections of liver and spleen and polymerase chain reaction analysis of peripheral blood, bone marrow, liver, spleen and lymph nodes confirmed the presence of bcr-abl+ leukemia cells in these murine tissues, while Western blot data demonstrated the expression of the fusion protein in 12B1 cells. Immunization of mice with dendritic cells (DC) loaded with the synthetic bcr-abl chimeric nonapeptide, GFKQSSKAL, led to a 150 times higher frequency of bcr-abl-specific CTL precursors in the spleen than in mice immunized with peptide alone. In vitro re-stimulation of DC-peptide-primed splenocytes resulted in substantial secretion of interferon gamma and augmented cytolytic activity against 12B1 targets. Finally, vaccination with peptide-loaded DC significantly prolonged survival of BALB/c mice that were challenged with 12B1 leukemia. The capacity to generate bcr-abl-specific CTL in vivo by DC-based immunization may have clinical implications in the treatment of CML.
He
L
L
University of Arizona, Department of Pediatrics, Steele Memorial Children's Research Center, 1501 N. Campbell Ave., PO Box 245073, Tucson, Arizona 85724-5073, USA.
Feng
H
H
Raymond
A
A
Kreeger
M
M
Zeng
Y
Y
Graner
M
M
Whitesell
L
L
Katsanis
E
E
D000818:Animals; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000032:analysis / Q000276:immunology*; D007114:Immunization; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D009842:Oligopeptides / Q000032:analysis / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured
D009842:Oligopeptides; D011993:Recombinant Fusion Proteins; C521957:glycyl-phenylalanyl-lysyl-glutaminyl-seryl-seryl-lysyl-alanyl-leucine; D016044:Fusion Proteins, bcr-abl